Approval · Notice of Compliance 15044 · 2013
ULORIC: Notice of Compliance 15044
Issued December 10, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15044
- Date
- December 10, 2013
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph based on safety information from psur for the period october 2011 to april 2012, and from the results of drug interaction studies with theophylline and rosiglitazone
- Therapeutic class
- Xanthine oxidase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ULORIC | Not yet assigned | — |
Medicinal ingredients
- FEBUXOSTAT 80 MG per TAB